{"nctId":"NCT00431132","briefTitle":"Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis","startDateStruct":{"date":"2007-01"},"conditions":["Menopause","Postmenopausal Vaginal Atrophy"],"count":336,"armGroups":[{"label":"Vagifem® 10 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: estradiol, 10 mcg"]}],"interventions":[{"name":"estradiol, 10 mcg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal women whose last menstruation was at least two years prior to the time of screening\n* At least 1 urogenital symptom (vaginal dryness, vaginal and/or vulvar irritation/itching, vaginal soreness, dysuria, dyspareunia and vaginal bleeding associated with sexual activity\n* Generally healthy\n\nExclusion Criteria:\n\n* Exposure to exogenous sex steroid hormones (estrogen and/or progestin hormone replacement therapy) within past 3 months","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies","description":"The endometrial hyperplasia rate was calculated based on the number of patients with endometrial hyperplasia/endometrial carcinoma divided by the total number of subjects with interpretable biopsies at Week 52.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Transvaginal Ultrasound: Endometrial Thickness","description":"Transvaginal ultrasounds were performed at Baseline (Week 0) and Week 52, or at the time of withdrawal in the case of a subject's premature discontinuation. Endometrial thickness, measured (double layer) in mm, were lesser than 4 mm for entry into the trial.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":336},"commonTop":["Nasopharyngitis"]}}}